Search Results - "Gonzalez Santiago, S."

SEOM clinical guidelines in hereditary breast and ovarian cancer (2019) by González-Santiago, S., Ramón y Cajal, T., Aguirre, E., Alés-Martínez, J. E., Andrés, R., Balmaña, J., Graña, B., Herrero, A., Llort, G., González-del-Alba, A.

“…Mutations in BRCA1 and BRCA2 high penetrance genes account for most hereditary breast and ovarian cancer, although other new high-moderate penetrance genes…”
Get full text

Psychosis secondary to indomethacin. A case report by González, S. Santiago, Sánchez-Lafuente, C. Gómez, Rico, A. Martinez, Molina, J. Hurtado

“…IntroductionIndomethacin, a non-steroidal anti-inflammatory treatment used in various inflammatory diseases, is one of the drugs that has been related to the…”
Get full text

Psychological impact of multigene cancer panel testing in patients with a clinical suspicion of hereditary cancer across Spain by Esteban, I., Vilaró, M., Adrover, E., Angulo, A., Carrasco, E., Gadea, N., Sánchez, A., Ocaña, T., Llort, G., Jover, R., Cubiella, J., Servitja, S., Herráiz, M., Cid, L., Martínez, S., Oruezábal‐Moreno, M.J., Garau, I., Khorrami, S., Herreros‐de‐Tejada, A., Morales, R., Cano, J.M., Serrano, R., López‐Ceballos, M.H., González‐Santiago, S., Juan‐Fita, M.J., Alonso‐Cerezo, C., Casas, A., Graña, B., Teulé, A., Alba, E., Antón, A., Guillén‐Ponce, C., Sánchez‐Heras, A.B., Alés‐Martínez, J.E., Brunet, J., Balaguer, F., Balmaña, J.

“…Objective Patients' psychological reactions to multigene cancer panel testing might differ compared with the single‐gene testing reactions because of the…”
Get full text

SEOM clinical guidelines on cardiovascular toxicity (2018) by Virizuela, J. A., García, A. M., de las Peñas, R., Santaballa, A., Andrés, R., Beato, C., de la Cruz, S., Gavilá, J., González-Santiago, S., Fernández, T. L.

“…One of the most common side effects of cancer treatment is cardiovascular disease, which substantially impacts long-term survivor’s prognosis. Cardiotoxicity…”
Get full text

Replied to “Some remarks to SEOM clinical guidelines on cardiovascular toxicity (2018)” by Virizuela, J. A., Garcia, A. Martin, de las Peñas, R., Santaballa, A., Andrés, R., Beato, C., de la Cruz, S., Gavilá, J., González-Santiago, S., Fernández, T. López

Get full text

Utility of quantitative bone ultrasound to assess anastrozole effect on bone mass in patients with breast cancer by Calderon-Garcia, J.F, Gonzalez-Santiago, S, Lavado-Garcia, J.M, Lopez-Ceballos, M.H, Rey-Sanchez, P, Pedrera-Zamorano, J.D

Get full text

P006 Randomized Phase II trial evaluating three anti-diarrhoeal prophylaxis strategies in patients with HER2+/HR+ early breast cancer treated with extended adjuvant neratinib (DIANER GEICAM/2018-06) by González-Santiago, S., Gil-Gil, M., Carrasco, E., Martínez-Jáñez, N., Adamo, B., Antolín, S., Alonso, J.L., Vethencourt, A., Martínez-Vila, C., Galve, E., Rojo, F., Caballero, R., Casas, M., Cortazar, E., McCulloch, L., Vedovato, J.-C., Martín, M.

Get full text

P.0089 The placebo effect in clinical trials of modern antidepressants: a meta-analysis by Sanchez-Lafuente, C. Gomez, Gonzalez, S. Santiago, Parra, J. Guzman

Get full text

Purification, Characterization, and Substrate and Inhibitor Structure−Activity Studies of Rat Liver FAD-AMP Lyase (Cyclizing):  Preference for FAD and Specificity for Splitting Ribonucleoside Diphosphate-X into Ribonucleotide and a Five-Atom Cyclic Phosphodiester of X, either a Monocyclic Compound or a cis-Bicyclic Phosphodiester−Pyranose Fusion by Cabezas, Alicia, Pinto, Rosa María, Fraiz, Francisco, Canales, José, González-Santiago, Santiago, Cameselle, José Carlos

“…An enzyme with FAD-AMP lyase (cyclizing) activity, splitting FAD to AMP and riboflavin 4‘,5‘-phosphate (cFMN), was recently identified [Fraiz, F., et al…”
Get full text

12P Prevalence of functional and genomic homologous recombination deficiency (HRD) in germline RAD51C/D patients by Llop-Guevara, A., Torres-Esquius, S., Romey, M., Gutierrez-Enriquez, S., Nuciforo, P.G., Diez, O., Llort Pursals, G., Teule, A., Vallmajó, A., Diaz De Corcuera, I., Chirivella Gonzalez, I., Gonzalez Santiago, S., Sanchez Henarejos, P., Sanz Buxo, J., Guillen Ponce, C., Sanchez, A.B., Brunet Vidal, J.M., Denkert, C., Serra Elizalde, V., Balmaña, J.

Get full text

Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial by Villacampa, Guillermo, Falato, Claudette, Paré, Laia, Hernando, Cristina, Arumí, Miriam, Saura, Cristina, Gómez, Guadalupe, Muñoz, Montserrat, Gil-Gil, Miguel, Izarzugaza, Yann, Ferrer, Neus, Najera-Zuloaga, Josu, Montaño, Alvaro, Ciruelos, Eva, González-Santiago, Santiago, Villagrasa, Patricia, Gavilá, Joaquín, Prat, Aleix, Pascual, Tomás

“…Introduction: In the phase II CORALLEEN trial, patients with PAM50 luminal B early breast cancer (EBC) were randomised to neoadjuvant ribociclib plus letrozole…”
Get full text

GSTP1 and MTHFR polymorphisms are related with toxicity in breast cancer adjuvant anthracycline-based treatment by Zárate, R, González-Santigo, S, de la Haba, J, Bandres, E, Morales, R, Salgado, J, Gómez, A, Aranda, E, García-Foncillas, J

“…We have analyzed several members of drug-metabolizing enzymes (DMEs) and other polymorphisms in genes implicated in tumor aggressivity regarding possible links…”
Get more information

P.0146 Trends in psychiatric hospitalizations of patients with personality disorders by Martín, E. Sánchez, González, S. Santiago, García, A.B. Mulero

Get full text

P.0740 Depression in patients with mild cognitive impairment as a predictor of caregiver burden by Guerrero, G. Pérez, Martínez, E. Sánchez, González, S. Santiago

Get full text

795P Tolerability and effectiveness of niraparib in long-term responders with platinum-sensitive recurrent ovarian cancer (GEICO-88R study) by Cueva Banuelos, J.F., Salvador Coloma, C., Galvez Montosa, F., Ferreiro Quintana, J., Cros Costa, S., González-Santiago, S., Cassinello, J.G., Romeo Marin, M., Reche, P., Soriano Tabares, M.L., Valero Arbizu, M., Rubio Perez, M.J., Oré Arce, H.M., Gaba Garcia, L., Gordon Santiago, M.D.M., Gomez Raposo, C., Hernando Polo, S., Marquez Vazquez, R., Fuentes Pradera, J., Gonzalez Martin, A.

Get full text

CYP2D64 polymorphism as blood predictive biomarker of breast cancer relapse in patients receiving adjuvant tamoxifen by Gonzalez-Santiago, S., Zárate, R., Haba-Rodríguez, J., Gómez, A., Bandrés, E., Moreno, S., Borrega, P., García-Foncillas, J., Aranda, E.

“…Abstract only 590 Background: Polymorphisms in cytochrome P450 2D6 gene affect the plasma concentration of tamoxifen active metabolites (endoxifen). Some drugs…”
Get full text

330TiP Trastuzumab deruxtecan (T-DXd; DS-8201) in HER2-positive (HER2+) and HER2-low expressing (HER-LE) metastatic breast cancer (MBC) with brain metastases (BM) and/or leptomeningeal carcinomatosis (LMC): DEBBRAH by Vaz Batista, M., Pérez-Garcia, J.M., Llombart Cussac, A., Cortez, P., Ruiz Borrego, M., De La Haba, J., Cejalvo, J.M., Racca, F., Servitja, S., Blanch, S., Lema, L., Galàn Garmaje, M., Fernández-Abad, M., Fernández, A., Iranzo, V., González-Santiago, S., Gion, M., Nave, M., Cortés, J., Braga, S.

Get full text

332TiP SOLTI-1907 ATREZZO: Targeting hormonal receptor negative (HR-) or PAM50 non-luminal disease with atezolizumab in combination with trastuzumab and vinorelbine in HER2+ metastatic breast cancer (MBC) by Ciruelos, E.M., Pernas, S., Perelló, A., Lopez, A., Salvador Bofill, F.J., Cejalvo, J.M., Blancas, I., Ponce Lorenzo, J., Servitja, S., Perez, M., Cruz, J., Albacar, C., Escrivá-de-Romaní, S.I., Guerra, J.A., González-Santiago, S., Sanfeliu, E., Rodriguez, C., Tolosa, P., Ferrero-Cafiero, J.M., Prat, A.

Get full text

The prognostic value of respiratory symptoms and performance status in ambulatory cancer patients and unsuspected pulmonary embolism; analysis of an international, prospective, observational cohort study by Maraveyas, Anthony, Kraaijpoel, Noémie, Bozas, George, Huang, Chao, Mahé, Isabelle, Bertoletti, Laurent, Bartels‐Rutten, Annemarieke, Beyer‐Westendorf, Jan, Constans, Joel, Iosub, Diana, Couturaud, Francis, Muñoz, Andres J., Biosca, Mercedes, Lerede, Teresa, van Es, Nick, Di Nisio, Marcello

“…Background Optimal risk stratification of unsuspected pulmonary embolism (UPE) in ambulatory cancer patients (ACPs) remains unclear. Existing clinical…”
Get full text

Abstract P6-17-31: Real world evidence of neoadjuvant treatment based on dual blockade with pertuzumab plus trastuzumab for early HER2+ breast cancer: The NeoPETRA study by Chacón, JI, Saura, C, Ciruelos, E, Alonso, JI, de la Morena, P, Santisteban Eslava, M, Gallegos, I, de Luna, A, Dalmau, E, González-Santiago, S

“…Background: Evidence from clinical trials supports the neoadjuvant use of pertuzumab and trastuzumab with chemotherapy to improve the pathologic complete…”
Get full text